Conditions: Diabetes Diabetes Mellitus, Type 2
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 813
Healthy volunteers: no

Brief summary:
This trial is conducted in Europe and North and South America. The aim of the trial is to investigate the efficacy and safety of semaglutide once-weekly versus exenatide ER (extended release) 2.0 mg once-weekly as add-on to 1-2 oral antidiabetic drugs (OADs) in subjects with type 2 diabetes.

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: semaglutide intervention 2: exenatide
Intervention descriptions: intervention 1: One dose of 1.0 mg semaglutide administered subcutaneously (s.c., under the skin) once-weekly intervention 2: One dose of 2.0 mg exenatide ER administered subcutaneously (s.c., under the skin) once-weekly

Protocol document: